Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...

Eli Lilly & Co.’s full-year earnings forecast came in line with analysts’ estimates as the company works to fix inventory ...

the board of directors of Eli Lilly and Company (NYSE: LLY) approved a new $15 billion share repurchase program. The company's prior $5 billion share repurchase program was completed in the fourth ...

Feb 5 (Reuters) - Eli Lilly (LLY.N), opens new tab investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales of popular weight-loss drug ...

Eli Lilly and Company (NYSE:LLY) has a strong presence in oncology, immunology, and neuroscience, and is investing in new technologies and partnerships to drive innovation in these areas.

(RTTNews) - While reporting financial results for the fourth quarter on Thursday, drugmaker Eli ... company said the growth in revenue compared to 2024 is expected to be largely driven by new ...

Q4 2024 Management View CEO David Ricks highlighted a 45% revenue growth in Q4, with significant contributions from Mounjaro and Zepbound. He emphasized ongoing expansion in manufacturing to meet ...

On Monday, Eli Lilly And Co (NYSE:LLY) inked two strategic collaborations ... to research and develop cancer treatments. Under this new agreement, the parties will leverage AdvanCell's proprietary ...

He also noted operating income more than doubling to $5.6 billion, supported by strong new product sales. The company provided ... product differentiation. Eli Lilly ended 2024 on a strong note ...